LG Chem's Gemiglo Exceeds KRW 1 trillion in First-Time Accumulated Prescription for Diabetes Drugs in Korea
Mar 17, 2025
|
LG Chem announced on the 17th that the total amount of extra-extraordinary prescriptions (Uvist market data) of 'Gemiglo'-based product lines (Gemiglo, Gemimet, Gemidapa, and Gemirow) reached KRW 1.659 trillion from December 2012 to December 2024. Domestic diabetic drug brands that have exceeded KRW 1 trillion in sales have grown for 11 consecutive years since their launch for the first time, with an annual average growth rate of 35%.
LG Chem succeeded in developing new drugs in 2012 by challenging localization for the first time in Korea in 2003 in the diabetes market dominated by products from overseas pharmaceutical companies, and launched Gemiglo in December of the same year. Since then, it took 10 years to leap to the top of the domestic diabetes market worth 1 trillion won. It has become the first market share leader in 2023, and is showing steady growth in 2024, recording 153 billion won in sales, up 6% year-on-year. LG Chem currently analyzes that more than 500,000 diabetics take the Gemigolo family.
Son Ji-woong, head of LG Chem's life science business division, said "We will continue to focus on research and development of new drugs and do our best to develop medicines that can provide patients with a better life."."
This article was translated by Naver AI translator.
